Mirum Q2 revenue rises 64%, raises 2025 guidance
Overview
Mirum Q2 2025 revenue grows to $128 mln, driven by Livmarli sales
Company raises 2025 revenue guidance to $490-$510 mln
Mirum reports Q2 net loss of $5.9 mln despite revenue growth
Outlook
Mirum raises 2025 revenue guidance to $490-$510 mln
Company expects Volixibat VISTAS study topline data in Q2 2026
Mirum plans Phase 2 MRM-3379 study in Fragile X Syndrome in Q4 2025
Result Drivers
LIVMARLI SALES - Livmarli net product sales reached $88.2 mln, marking an 87% growth over Q2 2024
INTERNATIONAL SUCCESS - Strong performance from international business and U.S. PFIC launch contributed to revenue growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Sales |
| $127.78 mln |
|
Q2 Net Income |
| -$5.86 mln |
|
Q2 Basic EPS |
| -$0.12 |
|
Q2 Operating Expenses |
| $132.77 mln |
|
Q2 Operating Income |
| -$4.99 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $73.00, about 29% above its August 5 closing price of $51.84
Press Release: ID:nBwZ0m9ta
